PM Portfolio Manager Reports

From Portfolio Manager reports

Security report / ILMN

ILMN Operating Console

Illumina is a cleaner post-GRAIL sequencing-platform recovery, but it still has a live proof burden. Q1 showed better NovaSeq X placements, recurring consumables strength, raised EPS and margin guidance, and strong free cash flow. The next evidence has to show repeat utilization, China stabilization, clean GAAP to non-GAAP margin bridges, SomaLogic contribution, and capital discipline before the September 2026 debt maturity.

Metadata Knowledge Lane Fallback Chart
Ticker ILMN
Knowledge reviewed 2026-06-07
Links checked 2026-06-21
Chart source Local API
Module 01 / Price

Selected-Security Chart

API required

Loading ILMN daily chart from the local report API.

Loading ILMN chart...

Module 02 / Proof window

Current Company View

Recovery proof
Next read Q2 and Q3 must show NovaSeq X utilization and consumables pull-through, not just one strong placement quarter.
Measured base

Q1 2026 revenue was $1.091B, up 4.8%, with consumables at $797M or about 73% of revenue.

Main proof issue

More than 80 NovaSeq X placements beat the 50-60 target range, but utilization and consumables decide the economics.

Quality caveat

FY2026 revenue guide remains 4%-6% growth, while margin and EPS improvement depend on non-GAAP bridge quality.

Next evidence

Greater China revenue, NIH and customer funding, SomaLogic contribution, buyback pace, and the September 2026 note maturity.

Q1 revenue $1.091B +4.8% year over year
Q1 consumables $797M About 73% of revenue
NovaSeq X >80 Q1 placements vs. 50-60 target
Q1 FCF $251M $289M OCF less $38M capex
Greater China $52M Down from $72M in Q1 2025
FY2026 EPS guide $5.15-$5.30 Raised after Q1
Exposure Map

Business Profile, Segments, And Exposure

Illumina sells sequencing and microarray instruments, consumables, services, software, and genomic-analysis workflows. The business is one Core Illumina reporting segment, so revenue mix and utilization matter more than product-level margin claims.

Business model

Installed base feeds recurring consumables

Instruments expand the installed base, but the economic read comes from sequencing consumables, clinical usage, service revenue, and customer funding that keeps labs active.

Disclosure map

One Core Illumina segment

Product and geography revenue are visible, but the filed source does not support high-confidence profit by sequencing, microarray, service, or SomaLogic lane.

Consumables engine

Main revenue pool.

FY2025 consumables were $3.227B of $4.343B revenue; Q1 2026 consumables were $797M of $1.091B.

More useful evidence

Consumables growth across installed NovaSeq X systems and clinical sequencing accounts.

NovaSeq X

Placement strength needs utilization.

Q1 placements exceeded 80 versus management's 50-60 target range.

More useful evidence

Placed instruments converting into recurring consumables and stable service revenue.

Greater China

Measured regional drag.

Q1 2026 Greater China revenue was $52M versus $72M a year earlier after a $65M FY2025 regional decline.

More useful evidence

Revenue stabilization and regulatory commentary tied to the unreliable-entities-list issue.

SomaLogic and multiomics

Strategic but unproven.

SomaLogic closed in January 2026 with about $460M total purchase price, including $382M cash and $81M contingent consideration.

More useful evidence

Cross-sell, retention, revenue contribution, and margin impact after integration.

Value Driver Board

Relative Value And Value Drivers

ILMN has already repriced from the overhang period. The useful driver checks are utilization, margin quality, China stabilization, and cash allocation rather than one-quarter instrument placement strength.

Utilization
>80 Q1 placements

The placement number supports recovery only if installed systems keep pulling consumables.

Next: Q2/Q3 placements, utilization, and consumables commentary.
Margin bridge
23.4%-23.6% guide

FY2026 non-GAAP operating margin guide improved after Q1, but adjustments still need quarterly review.

Next: GAAP/non-GAAP bridge, restructuring, acquisition, intangible, and tax items.
China
-$20M Q1 drag

Greater China pressure can offset ex-China execution and reduce margin conversion.

Next: regional revenue and unreliable-entities-list commentary.
Capital allocation
$500M maturity

September 2026 notes make buybacks, SomaLogic spend, and liquidity a visible capital discipline test.

Next: cash balance, repayment or refinancing, and buyback pace.
Guidance Tests

Guidance Path And What Changed

After Q1 2026, management raised FY2026 revenue to $4.52B-$4.62B, non-GAAP operating margin to 23.4%-23.6%, and non-GAAP EPS to $5.15-$5.30. The reported revenue-growth frame remained 4%-6%.

Question
Can NovaSeq X repeat beyond Q1?

Confirm Q2/Q3 placements, utilization, and consumables growth stay strong without leaning on one-time instrument demand.

Warn if placements fall sharply or consumables growth does not follow the installed-base expansion.

Question
Is margin expansion clean?

Confirm GAAP and non-GAAP margins both improve with clear acquisition, restructuring, intangible, contingent consideration, investment, and tax bridges.

Warn if adjusted EPS improves while exclusions carry the margin story.

Question
Does capital allocation stay flexible?

Confirm FCF covers buybacks, SomaLogic integration, R&D, capex, and the 2026 debt maturity without reducing liquidity.

Warn if buybacks keep absorbing cash while debt or integration costs tighten flexibility.

Operating Evidence

Operating Evidence And KPIs

These tiles summarize the filed source evidence. Use the lane and raw outputs for the full claim map.

Recovery base
$1.091B

Q1 revenue rose 4.8% year over year, with consumables still the core revenue pool.

Cash conversion
$251M FCF

Q1 operating cash flow was $289M and capex was $38M.

China pressure
-$20M

Q1 Greater China revenue fell by $20M year over year.

Margin quality
19.2% / 21.9%

Q1 GAAP and non-GAAP operating margins both matter for the quality read.

Capital Ledger

Financial Quality And Capital Allocation

The balance sheet is serviceable, but cash uses are active. SomaLogic, buybacks, capex, R&D, and the 2026-2027 debt ladder all compete for the same cash generation.

Liquidity and maturities

$1.155B cash plus short-term investments

At March 29, 2026, Illumina had $1.089B cash, $66M short-term investments, $1.989B net carrying term debt, and an undrawn $750M revolver. The first $500M note maturity is September 2026.

Buybacks and M&A

$243M repurchased in Q1 2026

Buybacks follow $742M in FY2025 repurchases and a new $1.5B authorization. SomaLogic adds a separate cash and integration test after the January close.

Position Board

Competitive Position

Illumina has a real sequencing-platform edge, but it is narrower than a clean monopoly story because customer funding, China, and multiomics integration can all reduce utilization or margin conversion.

What ILMN has

Installed-base economics

Sequencing instruments feed recurring consumables and services when utilization remains healthy.

NovaSeq X transition

Q1 placements above target support the recovery path if later consumables show pull-through.

Cash generation

Q1 FCF and FY2025 FCF provide flexibility for buybacks, debt, M&A, and R&D.

What is not proven

Utilization durability

One strong placement quarter does not prove repeat consumables pull-through.

China stabilization

Greater China remains a quantified drag and regulatory timing is unresolved.

SomaLogic economics

Multiomics expansion is plausible, but cross-sell, retention, revenue, and margin contribution are still open.

Street View

Ownership, Flows, Valuation, And Street Views

Official filings and Illumina releases carry the operating evidence. Outside market-data items are dated context and should be refreshed before trading-sensitive use.

Official source set

IR, filings, and releases checked 2026-06-21

Illumina source routes include the Q1 release, FY2025 10-K, Q1 10-Q, 2026 proxy, May 2026 8-K, SomaLogic close, NovaSeq roadmap, and StrataMap launch.

Dashboard use: source routing and filing freshness. Illumina investor relations
Valuation frame

Recovery multiple after the overhang period

The filed lane frames June 5 public market data around a $162.32 price, $24.56B market cap, about 26x P/E, 20x EV/EBITDA, and 24x EV/FCF.

Dashboard use: proof burden, not a live quote. Knowledge lane valuation section
Outside-view market data

StockAnalysis statistics checked 2026-06-21

The outside-view statistics page was used only as dated market context because the lane flags public market data as directional rather than deterministic.

Dashboard use: valuation context; local chart API remains the report chart source. StockAnalysis ILMN statistics
Flow context

Buybacks matter more than short interest

The filed source treats ownership flows as secondary: institutional holders are meaningful, short interest is moderate, and buyback pace is the capital-allocation signal to watch.

Dashboard use: flow sensitivity, not a standalone thesis. MarketBeat ILMN short interest
Scenario Board

Scenario Assessment And Sensitivities

The base case is controlled recovery. Upside needs utilization and funding to improve together; downside starts with weak consumables pull-through, China pressure, or margin bridge deterioration.

Base

NovaSeq X and clinical consumables support revenue, margin guide is mostly met with acceptable bridge quality, China remains a drag but does not worsen, and FCF covers active cash uses.

Upside

Consumables growth broadens, NovaSeq X utilization repeats, customer funding improves, China stabilizes, and SomaLogic becomes additive without sustained margin dilution.

Downside

Growth narrows, China declines accelerate, funding-sensitive customers delay instruments, non-GAAP adjustments carry the margin story, and buybacks reduce flexibility ahead of maturities.

Trigger Stack

Monitoring Triggers

These are business evidence checks. Chart overlays remain in the shared overlay rules, outside this page.

NovaSeq X

Placement quality and utilization

Confirm Q2/Q3 placements, utilization, and consumables stay strong.

Warn if placement strength fades or consumables do not follow installed-base growth.

China

Greater China revenue and regulatory path

Confirm China stabilizes against the Q1 $52M revenue base.

Warn if the drag worsens beyond the Q1 $20M year-over-year decline.

Margin bridge

GAAP and non-GAAP quality

Confirm operating margin improvement is visible in both GAAP and adjusted metrics.

Warn if exclusions or acquisition adjustments become the main source of EPS progress.

Funding

NIH and customer budget sensitivity

Confirm academic, government, biotech, pharma, and diagnostic customers keep order timing stable.

Warn if customer budgets delay instruments or reduce utilization.

SomaLogic

Multiomics contribution

Confirm revenue contribution, retention, cross-sell, and manageable margin impact.

Warn if integration remains dilutive without measurable platform benefit.

Cash use

Debt, buybacks, and liquidity

Confirm the September 2026 debt maturity is handled without reducing operating flexibility.

Warn if buybacks stay large while cash balance or refinancing flexibility weakens.

Risk Punch Cards

Risks, Invalidations, And Quality Flags

The main risks are NovaSeq X utilization, Greater China, customer funding, non-GAAP bridge quality, SomaLogic integration, and buybacks before debt maturities.

Utilization risk
Basis

NovaSeq X placements were strong in Q1, but the revenue model depends on consumables usage.

Warning

Placements do not convert into repeat consumables pull-through.

Reduce concern

Multiple quarters show strong utilization and broader clinical consumables growth.

Greater China
Basis

China has already reduced revenue in FY2025 and Q1 2026.

Warning

Regulatory pressure or customer access worsens and offsets ex-China recovery.

Reduce concern

Regional revenue stabilizes and management stops attributing decline to the unreliable-entities-list issue.

Funding-sensitive customers
Basis

Academic, government, biotech, pharma, clinical, and diagnostic customers can delay purchases under funding pressure.

Warning

NIH, credit, or customer capex pressure slows orders and utilization.

Reduce concern

Instrument timing and consumables demand hold across customer groups.

Margin bridge quality
Basis

Non-GAAP metrics are central to guidance and compensation metrics.

Warning

Recurring exclusions, contingent consideration, investment gains/losses, or acquisition costs drive EPS growth.

Reduce concern

GAAP earnings, adjusted earnings, operating margin, and cash flow point in the same direction.

SomaLogic integration
Basis

The acquisition adds multiomics reach but initially dilutes 2026 EPS and operating margin.

Warning

Revenue contribution does not offset cross-sell, retention, and margin integration costs.

Reduce concern

Management discloses durable revenue contribution and manageable margin effect.

Buybacks with maturities
Basis

Buybacks are large while $500M notes mature in 2026 and another $500M mature in 2027.

Warning

Cash returns reduce flexibility before debt, M&A, R&D, or customer-cycle needs are settled.

Reduce concern

Debt is handled cleanly and cash generation remains comfortably above capital uses.

Diagnostics

Diagnostics, Freshness, And Known Unknowns

This report is a projection of the filed ILMN lane with dated official web checks. It does not refresh canonical research.

Freshness

Lane source run generated 2026-06-07
Source run

Latest paired ILMN profile and research projections were generated 2026-06-07T23:02:00Z.

Market data

Lane market data is directional as of June 5 and late May public pages, not a deterministic live quote.

Web check

Official IR, Q1 release, 10-Q, 10-K, proxy, latest 8-K, and official releases were checked 2026-06-21.

Known unknowns

Proof still needed
Transcript history

Only Q4 2025 and Q1 2026 transcripts were directly inspected upstream.

Investor deck and debt detail

The latest investor presentation, debt indentures, and rating-agency commentary were not directly reviewed.

Form 4 and market data

Primary recent Form 4 review was incomplete and outside market data should be refreshed before precise flow claims.

Categories